Company / Free Cash Flow
Vir Biotechnology, Inc. Free Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$396.6M
FY2025
5-year range
-$800.4M / -$138.6M
FY2021-FY2025
Trend
+12.6%
vs FY2024
Sector context
#182 of 194
Health Care
What the data says
Among 194 Health Care companies, Vir Biotechnology, Inc. is in the bottom 6% for free cash flow. Free Cash Flow has fluctuated over the past 9 years, ranging from -$800M in FY2023 to -$69M in FY2017.
Based on SEC 10-K filings.
-$397M in FY2025.
Improved from -$800M to -$397M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 194This company -$396.6M Sector average $470.6M
▼
-184.3% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 12.6% year-over-year.
- Ranks #182 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$396.6M | +12.6% |
| FY2024 | -$453.7M | +43.3% |
| FY2023 | -$800.4M | -305.3% |
| FY2022 | -$197.5M | -42.5% |
| FY2021 | -$138.6M | +29.8% |
| FY2020 | -$197.5M | -42.5% |
| FY2019 | -$138.6M | -35.5% |
| FY2018 | -$102.3M | -48.0% |
| FY2017 | -$69.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026